1-6 of 6
Francis Seguy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Sanjay Mohan, Stephen Oh, Jean-Jacques Kiladjian, Masahiro Takeuchi, Jason Gotlib, Ellen K. Ritchie, Taizo Shimomura, Paola Guglielmelli, Anthony M. Hunter, Francesca Palandri, Francoise Boyer, Alessandro Rambaldi, Takehiko Mori, Tomoki Ito, Betty Lamothe, Yan-Ou Yang, Yi Cui, Francis Seguy, Amanda McBride, Prithviraj Bose
Journal: Blood
Blood (2023) 142 (Supplement 1): 624.
https://doi.org/10.1182/blood-2023-179291
Published: 2023
Journal Articles

INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study

Justin Watts, Anthony M. Hunter, Alessandra Iurlo, Blanca Xicoy, Francesca Palandri, Brandi Reeves, Alessandro M. Vannucchi, Xuejun Chen, Francis Seguy, Feng Zhou, Fred Zheng, Pankit Vachhani
Journal: Blood
Blood (2022) 140 (Supplement 1): 9696–9697.
https://doi.org/10.1182/blood-2022-169740
Published: 2022
Journal Articles

A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)

Sanjay R Mohan, Stephen T Oh, Haris Ali, Anthony M. Hunter, Francesca Palandri, Betty Lamothe, Yi Cui, Francis Seguy, Amanda McBride, Michael Robert Savona, Jean-Jacques Kiladjian, Srdan Verstovsek
Journal: Blood
Blood (2022) 140 (Supplement 1): 3943–3944.
https://doi.org/10.1182/blood-2022-169210
Published: 2022
Journal Articles

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Stephen T. Oh, MD, Jason Gotlib, MD MS, Sanjay Mohan, MD MSCI, Haris Ali, MD, Ekatherine Asatiani, MD, Francis Seguy, Feng Zhou, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3.
https://doi.org/10.1182/blood-2020-134574
Published: 2020
Journal Articles

Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

Antonio Almeida, MD PhD, Valeria Santini, MD, Stefanie Gröpper, MD, Anna Jonasova, MD, Norbert Vey, Aristoteles Giagounidis, MD PhD, Eva Hellström-Lindberg, MD PhD, Ghulam J. Mufti, MD PhD, Guillermo Sanz, MD PhD, Barry Skikne, MD, Albert Hoenekopp, MD, Francis Séguy, Jianhua Zhong, PhD, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2880.
https://doi.org/10.1182/blood.V126.23.2880.2880
Published: 2015
Journal Articles

Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)

Valeria Santini, MD, Antonio Almeida, MD PhD, Aristoteles Giagounidis, MD PhD, Stephanie Gröpper, MD, Anna Jonasova, MD, Norbert Vey, MD PhD, Ghulam J. Mufti, MD PhD, Rena Buckstein, MD, Moshe Mittelman, MD, Uwe Platzbecker, MD, Ofer Shpilberg, MD, Ron Ram, MD, Consuelo del Canizo, MD PhD, Norbert Gattermann, MD PhD, Keiya Ozawa, MD PhD, Jim Zhong, PhD, Francis Séguy, Albert Hoenekopp, MD, C.L. Beach, MD, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2014) 124 (21): 409.
https://doi.org/10.1182/blood.V124.21.409.409
Published: 2014